# US 2024/0254108 A1 · Compound comprising pyrrolidine as linker, and pharmaceutical composition comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254108 A1
- Document ID: US20240254108A1
- Status: Published application
- Kind: A1
- Application number: 18/289,872
- Filed: 2022-04-19
- Published: 2024-08-01
- Earliest claimed: 2021-05-11
- Assignees: Bead Tech Inc.; Sogang University R&Db Foundation
- Applicants: Bead Tech Inc.; Sogang University R&Db Foundation
- Inventors: Yoon Sik LEE; Seok In KIM; Bong Gun JU; Ha Yan JEONG; Myeongok KIM
- Web page: https://patentgrep.com/patent/US20240254108A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound containing a pyrrolidine moiety as a linker or a pharmaceutically acceptable salt thereof. The present invention also relates to a composition for preventing and treatment of the respiratory diseases or the skin conditions such as atopy and psoriasis and bronchial diseases, including the compound as an active ingredient.

## Claims

### Claim 1

A compound represented by Formula 1:
wherein L is selected from the group consisting of a direct bond and C1-C5 alkylene, R1 is C6-C18 aryl, R2 is C2-C18 heteroaryl, R3 is selected from the group consisting of hydroxyl, hydroxyamino, amino, C1-C10 monoalkyl, and C1-C10 dialkylamino, and R4 is selected from the group consisting of hydrogen, hydroxyl, and C1-C10 alkyl, with the proviso that aryl as R1, heteroaryl as R2, monoalkyl or dialkylamino as R3, and alkyl as R4 are each independently unsubstituted or substituted with one or more substituents selected from the group consisting of hydroxyl, amino, C1-C10 alkyl, C1-C10 alkyloxy, and C6-C18 aryl, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of Formula 1 is represented by Formula 2:
wherein R2 to R4 and L are as defined in claim 1 and R5 to R9 are the same as or different from each other and are each independently selected from the group consisting of hydrogen, hydroxyl, C1-C5 alkyloxy, and C1-C5 alkyl, with the proviso that at least one of R5 to R9 is optionally hydroxyl.

### Claim 3 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of Formula 1 is represented by one of Formulas 3 to 6:
wherein R2 to R9 and L are as defined in claims 1. R5 to R9 are the same as or different from each other and are each independently selected from the group consisting of hydrogen, hydroxyl, C1-C5 alkyloxy, and C1-C5 alkyl, with the proviso that at least one of R5 to R9 is optionally hydroxyl.

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R2 is imidazolyl.

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is amino.

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein L is selected from the group consisting of a direct bond, methylene, and ethylene.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the compound or pharmaceutically acceptable salt thereof inhibits the expression of thymic stromal lymphopoietin (TSLP), interleukin (IL) or granulocyte colony stimulating factor (G-CSF).

### Claim 9 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the composition is for the prevention and treatment of the respiratory diseases or the skin conditions that are selected from the group consisting of atopic dermatitis, eczema, psoriasis, contact dermatitis, and cutaneous pruritus.
